A Plan to Conquer U.S. Drug Shortages

By JESSICA DALEY and WAYNE RUSSELL COVID-19 has focused the nation’s attention on the risks associated with complex, global supply chains, particularly related to healthcare products and prescription drugs. While supply disruptions of personal protective equipment (PPE) captured headlines, the pandemic also compromised the drug supply chain. With much of the United States’ generic drugs manufactured overseas, exportation bans coupled with increased global demand created significant challenges for U.S.-based providers to secure basic, life-sustaining and life-saving therapies. As an “easy” solution, many are now calling for manufacturers to produce medications domestically. While expanding investment in U.S. drug-making capacity is a vital component of a reliable supply strategy, moving the majority of production onshore is unrealistic. Creating a dependable drug supply chain is a multi-faceted issue that requires a thoughtful, diversified strategy. Repairing the Market is Job #1 Drug shortages have been pervasive for more than a decade – well before COVID-19’s onset. While shortages are triggered in a number of ways, arecent Food and Drug Administration (FDA) report says economics are a main causative factor. Almost all shortage drugs are older, low-cost generics costing less than $9/dose. Because these products don’t generate blockbuster profits, manufacturers are less willing to invest capital to improve quality, build redundant capac...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Pharmaceuticals The Business of Health Care Drug shortages Jessica Daley Premier Wayne Russell Source Type: blogs